Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effect of Combined Versus Monotherapy With Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients: A Randomized Clinical Trial Publisher



Hejazi S1 ; Safari O2 ; Arjmand R2 ; Qorbani M3, 4 ; Pourrostami K2 ; Safari A5 ; Hemmati A2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pediatrics, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
  2. 2. Department of Pediatrics, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran
  3. 3. Department of Community Medicine, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran
  4. 4. Department of Epidemiology, Non Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Psychology, Ilam Branch, Islamic Azad University, Ilam, Iran

Source: International Journal of Pediatrics Published:2016


Abstract

Background: Patients with transfusional iron overload have depended on iron chelation therapy and improving chelation regimens have been of the highest priority. The aim of this study was to compare effect of combined versus monotherapy with Deferoxamine (DFO) and Deferiprone (DFP) in iron overloaded beta thalassemia (BT) major patients Materials and Methods We studied 36 BT major patients (mean age 7.6±4.6; range 3-16 years) attending the Ormieh Motahari hospital for regular transfusional support. Patients were randomly allocated to receive one of the following two treatments: DFO in combination with DFP (n=12), DFO alone (n=12) and DFP alone (n=12). Serum ferritin level, liver enzymes, blood urea nitrogen, and creatinine and side effects were monitored over a 12 months period. Results: After one year, serum ferritin decreased more significantly in patients on DFO+DFP therapy compared to patients who only received DFO or DFP alone (P < 0.01). Side effects of DFP, including gastrointestinal upset (nausea, vomiting and abdominal pain) and mild agranulocytosis occurred in five (41.7%) and two (8.3%) patients, respectively but none led to discontinuation of the treatment. Conclusion: In comparison to the standard chelation monotherapy of DFO, combination treatment with additional DFP reduced serum ferritin and is effective procedure in clinical management of iron overload in patients with BT major.
Related Docs
1. Comparison of Iron Chelation Effects of Deferoxamine, Deferasirox, and Combination of Deferoxamine and Deferiprone on Liver and Cardiac T2* Mri in Thalassemia Maior, Caspian Journal of Internal Medicine (2017)
2. Survival Analysis of Thalassemia Major Patients Using Cox, Gompertz Proportional Hazard and Weibull Accelerated Failure Time Models, Medical Journal of the Islamic Republic of Iran (2017)
3. Evaluating the Safety and Efficacy of Silymarin in Β-Thalassemia Patients: A Review, Hemoglobin (2015)
4. Surrogate Markers of Subclinical Atherosclerosis and Its Associated Factors in Patients With Β-Thalassemia Major, Hemoglobin (2021)
5. Risk Factors Associated With Heart Failure in Patients With Β-Thalassemia, Iranian Heart Journal (2022)
6. Survival Analysis and Its Associated Factors of Beta Thalassemia Major in Hamadan Province, Iranian Journal of Medical Sciences (2015)
7. Two Trade Names of Deferasirox (Osveral® and Exjade®) in Reduction of Iron Overload Parameters in Major Betathalassemia Patients: A Randomized Open Labeled Clinical Trial, Caspian Journal of Internal Medicine (2022)
Experts (# of related papers)
View all Related Experts
Farshad Sharifi (1)
Hossein Fakhrzadeh (1)